ClinicalTrials.gg
CompletedNCT06799143Updated Jan 29, 2025

Copley II: Long-term Outcome Follow-up Study of Osteoporotic Women Who Underwent a Local Osteo-Enhancement Procedure (LOEP) in the Proximal Femur

An observational study in Osteopenic Women and Proximal Femur Fracture, sponsored by AgNovos Healthcare, LLC. Completed. Open to female participants aged 56 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by AgNovos Healthcare, LLC · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
12
Ages
56 Years and older
Sex
Female
01

Study summary

To evaluate longer-term (5-7 years) outcomes of the twelve (12) subjects treated with AGN1 Femoral LOEP in the clinical study "A Prospective Pilot Evaluation of Percutaneous Osteo-supplementation in the Proximal Femur of Osteoporotic Patients". Performance will be evaluated via medical history evaluation, X-ray, DXA, CT and mobility testing.

The study will look at the extent to which the benefits demonstrated in the initial, baseline study were sustained over time. In this manner, it may be possible to determine the rate of change in BMD following the treatment; thereby allowing prediction of the total benefit period. In addition, this longer period of observation allows for further evaluation of the safety profile of the material in osteoporosis patients.

Read the detailed description

This observational single arm study will be broken into two parts:

  1. A retrospective component which will evaluate the original FRAX score along with any events or medications received after the end of the original study.
  2. A prospective component which will evaluate longer term outcomes following the use of the AGN1 synthetic bone graft material in a local osteoenhancement procedure through evaluation of mobility and imaging.

In the original study, subjects completed a twenty-four (24) month follow-up visit after receiving a unilateral hip injection with the device. The contralateral hip acted as the control. The purpose of the study was to determine the safety of the injection as well as the initial improvement in femoral bone density in a twenty-four (24) month period.

In this follow-up study the subjects, after signing the informed consent form, will complete a short medical history (focused on their osteoporosis management) and a mobility test.

Subjects will also undergo a DXA, X-ray and CT scans of both hips.

02

Conditions studied

  • Osteopenic Women
  • Proximal Femur Fracture

Keywords

  • LOEP
  • osteoporosis
  • femur fracture
03

In context

Proximal Femoral Fractures

36 studies on the registry are indexed under Proximal Femoral Fractures; 6 are open to participants now.

This study's enrollment of 12 is below the median of 140 across 13 observational studies indexed under Proximal Femoral Fractures.

Browse Proximal Femoral Fractures studies →

Lead sponsor

AgNovos Healthcare, LLC is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
56 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Females aged 56 or older and menses have ceased for at least one year. Subjects that were participants in the original study that signed a consent form, received treatment with AGN1 Femoral LOEP and completed the original study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participated in the original study and signed the consent form
  • received treatment with AGN1 Femoral LOEP
  • completed the study.

Exclusion criteria

Exclusion Criteria:

  • There is no exclusion criteria for this study.
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
12 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Bone Mineral Density

    Bone mineral density (BMD) assessed by DXA scans (T-score ) of the treated hip compared to nontreated hip (femoral neck).

    Time frame: through study completion, an average of 30 days

  2. Bone Mineral Density

    Bone mineral density (BMD) assessed by DXA scans (absolute value measurement) of the treated hip compared to nontreated hip (femoral neck).

    Time frame: through study completion, an average of 30 days

  3. Bone Mineral Density

    Percent change compared to baseline for the treated femoral neck measurement of BMD.

    Time frame: through study completion, an average of 30 days

  4. Bone Mineral Density

    Percent change compared to baseline for the untreated femoral neck measurement of BMD.

    Time frame: through study completion, an average of 30 days

  5. Bone Mineral Density

    Bilateral hip CT scan analysis of the trabecular bone density.

    Time frame: through study completion, an average of 30 days

  6. Bone Mineral Density

    Bilateral hip CT scan analysis of the trabecular bone volume.

    Time frame: through study completion, an average of 30 days

  7. Bone Mineral Density

    Bilateral hip CT scan analysis of the cortical bone density.

    Time frame: through study completion, an average of 30 days

  8. Bone Mineral Density

    Bilateral hip CT scan analysis of the cortical bone volume.

    Time frame: through study completion, an average of 30 days

  9. Bone Mineral Density

    Bilateral hip CT scan analysis of any qualitative observations compared to baseline CT scans.

    Time frame: through study completion, an average of 30 days

Secondary outcomes

  1. Subject Interview

    All osteoporosis related events (as defined by the Investigator) from the twenty-four (24) month follow-up visit to current point-in-time including fragility fractures, changes in mobility and medication reactions.

    Time frame: through study completion, an average of 30 days

  2. Subject Interview

    All osteoporosis medication use including vitamins and supplements from the twenty-four (24) month follow-up visit to current point-in-time.

    Time frame: through study completion, an average of 30 days

  3. Subject Interview

    Any physical activity/exercise program from the twenty-four (24) month follow-up visit to current point-in-time.

    Time frame: through study completion, an average of 30 days

  4. FRAX Index Risk Assessment

    Comparative calculation of a FRAX index for hip fracture risk based on BMD data from the treatment and contralateral hip using pre-procedure data compared to current point-in-time.

    Time frame: through study completion, an average of 30 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Feb 2016, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2025
First posted
Jan 29, 2025
StartActual
Jan 13, 2016
Primary completionActual
Feb 25, 2016
CompletionActual
Apr 15, 2016
Last update
Jan 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06799143
Lead sponsor
AgNovos Healthcare, LLC
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Jan 13, 2016
Primary completion
Feb 25, 2016
Completion
Apr 15, 2016
Last update
Jan 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion